The NASH/MASH Treatment Market report is segmented By Drug (Resmetirom (Rezdiffra), Lanifibranor, Semaglutide, Survodutide, Pegozafermin, Efruxifermin, Denifanstat, Others), By Stage (Stage 0-1, Stage 2-3, Stage 4), By Age-Group (Pediatrics, Adults, Geriatrics), By Gender (Male, Female) and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa)
FOR IMMEDIATE RELEASE
LEANDER, Texas: The NASH or MASH treatment market is moving out of the long wait period. For years, the field had a large patient pool, heavy disease burden and a crowded pipeline, but no clear approved pharmacotherapy. That has changed.
According to DataM Intelligence, the global NASH/MASH Treatment Market reached US$ 8.13 billion in 2025 and is expected to reach US$ 40.95 billion by 2035, growing at a CAGR of 17.55% during 2026 to 2035. The market is segmented by drug, stage, age group, gender and region. Key drug categories include Resmetirom, Lanifibranor, Semaglutide, Survodutide, Pegozafermin, Efruxifermin, Denifanstat and others.
This market is growing because the disease burden is finally becoming more actionable. MASH is linked closely with obesity, type 2 diabetes, insulin resistance, metabolic syndrome and abnormal blood lipid levels. These conditions are rising globally, which expands the population at risk of liver inflammation, fibrosis, cirrhosis and liver failure. DataM Intelligence notes that MASH treatment options include lifestyle intervention, bariatric surgery and pharmacotherapy, with treatment selection often shaped by diabetes status, obesity profile and fibrosis stage.
North America Region Analysis: First Approved Therapy Gives the Region a Commercial Head Start
North America dominated the NASH/MASH treatment market with a 47% share in 2024. The region’s lead comes from higher diagnosis rates, stronger specialist infrastructure, large metabolic disease burden and early access to approved therapy. DataM Intelligence notes that the availability of Resmetirom helped strengthen North America’s position in the market.
The United States is the main driver. Adult obesity prevalence was 40.3% in the country, while more than 38 million Americans have diabetes and roughly 90% to 95% of those cases are type 2 diabetes. Hypertension is also highly prevalent, affecting nearly 1 out of 2 adults. This creates a large population at risk of MASH progression, especially when obesity, insulin resistance and type 2 diabetes overlap.
DataM estimates that total prevalent MASH cases in the US were approximately 17.50 million in 2024 and could reach 23.33 million by 2030. That is the commercial reason North America matters. It has the patients, the prescribing infrastructure and the first approved drug pathway. But it also has payer pressure. MASH drugs may face tight coverage rules because the eligible population is large and treatment duration can be long. Adoption will depend on non invasive testing, fibrosis confirmation, specialist access and real world outcomes.
Europe Region Analysis: Specialist Pathways Are Strong, But Access Will Decide Pace
Europe is likely to become one of the most important adoption markets as approved therapies expand beyond the United States. The region has strong hepatology and gastroenterology infrastructure, mature reimbursement systems and high awareness of metabolic liver disease. Germany and France stand out as strong country opportunities because they combine specialist care access with reimbursement capacity and structured treatment pathways.
The challenge is market access. European payers will not adopt MASH therapies only because the disease burden is high. They will want clear evidence on fibrosis improvement, durability of response, safety, patient selection and long term economic value. That means the market may develop more carefully than North America.
Europe’s opportunity sits in diagnosed patients with Stage 2 to 3 fibrosis, especially those with obesity, type 2 diabetes or other cardiometabolic risk factors. This is the group where pharmacotherapy has the strongest clinical and economic argument. If non invasive screening expands through primary care, endocrinology and hepatology pathways, Europe can become a high value region. If diagnosis remains slow, the market will underconvert despite the large at risk population.
Stage Segment Analysis: Stage 2 to 3 Becomes the Commercial Center
Stage 2 to 3 fibrosis is the most important segment in the NASH/MASH treatment market. DataM Intelligence reports that the Stage 2 to 3 segment was valued at US$ 3,237.06 million in 2024 and is estimated to reach US$ 19,391.01 million by 2032, growing at a CAGR of 27.2% during 2026 to 2032.
This segment matters because it represents the clearest intervention window. Patients have meaningful fibrosis and disease progression risk, but they are not yet in the most advanced cirrhotic stage where treatment becomes more complex. Stage 2 patients may still have liver damage that can be improved through lifestyle intervention and therapy. Stage 3 patients already have substantial scarring, which makes prevention of further progression a commercial and clinical priority.
Resmetirom changed the treatment pathway because it became the first FDA approved therapy for adults with non cirrhotic MASH and moderate to advanced fibrosis. DataM notes that the FDA label does not require liver biopsy, which could support broader use when non invasive fibrosis testing is available.
Drug Segment Analysis: Resmetirom Opened the Market, GLP 1 Drugs Broaden the Opportunity
Resmetirom is the anchor therapy in the current market because it created the first approved liver directed treatment pathway. The US FDA approved Rezdiffra in March 2024 for adult patients with MASH and moderate to advanced fibrosis, making it the first therapy in the category.
That first mover advantage matters. It gives Madrigal Pharmaceuticals an early commercial position, physician education opportunity and payer negotiation starting point. Still, the market will not remain a single drug story. DataM Intelligence highlights GLP 1 based MASH treatment as a fast growing use case because many MASH patients also have obesity or type 2 diabetes. Semaglutide strengthens the market by linking liver improvement with metabolic control.
The pipeline is becoming more competitive. Survodutide received FDA Breakthrough Therapy designation in October 2024 for adults with MASH and moderate to advanced fibrosis. Efruxifermin and pegozafermin remain closely watched FGF21 candidates, while tirzepatide has created strong interest through MASH resolution and fibrosis improvement data. The market is likely to move toward patient stratification rather than one uniform treatment model. Liver dominant patients may align more with liver directed drugs. Metabolic dominant patients may align more with GLP 1 or incretin based therapy. Combination and sequencing strategies will become more relevant as evidence matures.
Analyst Insight
“NASH or MASH treatment is entering its first true commercialization cycle. The largest opportunity is not every fatty liver patient. It is the diagnosed Stage 2 to 3 fibrosis population where intervention can reduce progression risk before cirrhosis changes the economics of care. Resmetirom opened the market, while GLP 1 and FGF21 based therapies will expand competition. The companies that win will need more than clinical data. They will need diagnosis support, payer access, physician education and clear patient targeting.”
About DataM Intelligence
DataM Intelligence is a market intelligence and strategic consulting firm specializing in high growth sectors including pharmaceuticals, biotechnology, healthcare, medical devices, diagnostics and life sciences. Through analyst led research, market assessment, competitive intelligence, pipeline analysis, KOL engagement and custom consulting, DataM Intelligence helps organizations identify growth opportunities, evaluate access risk, benchmark competitors and support stronger strategic decisions.
Media Contact
Company Name: DataM Intelligence 4Market Research
Contact Team: Media Relations and Analyst Inquiries
Email: [email protected]
Corporate Address: 2243 Rocoso TRL, Leander, TX 78641, USA
Official Website: https://www.datamintelligence.com
Topic: NASH/MASH Treatment Market
Download Sample Report: https://www.datamintelligence.com/download-sample/nash-or-mash-treatment-market